ROCO
4736
Market cap373mUSD
Nov 13, Last price
122.50TWD
Name
Taidoc Technology Corp
Chart & Performance
P/E
10.08
P/S
2.52
EPS
12.15
Div Yield, %
—
Shrs. gr., 5y
2.74%
Rev. gr., 5y
1.32%
Revenues
4.64b
-51.79%
Net income
1.16b
-65.75%
CFO
-181m
L
Dividend
Sep 04, 202319.98171 TWD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
TaiDoc Technology Corporation manufactures and markets medical devices worldwide. It offers In vitro diagnostics products, including blood glucose and multiple parameters monitoring systems, point of care testing devices, lancet and lancing devices, and vet health care products comprise blood glucose and calcium meters, and blood ketone meters; and medical devices, such as nebulizers, thermometers, blood pressure monitors, vital sign monitors, and pulse oximeters. The company also provides telehealth remote monitoring devices and smartphone applications; and Covid-19 antigen rapid test kits. In addition, it offers services for regulatory professionals, as well as in the areas of clinical suggestions, engineering resources, and manufacturing systems. TaiDoc Technology Corporation was founded in 1998 and is headquartered in New Taipei City, Taiwan.
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||